KLK3 and neoplasm: Prognostic factors that correlate with poorer outcomes for patients with metastatic disease include poor performance status, shorter prostate-specific antigen (PSA) doubling time, higher Gleason score, pain at presentation, high tumor volume, and visceral metastasis [7].